Strategic partnerships Opportunities to leverage existing relationships with Isoray and PharmaLogic to co-develop and manufacture radiopharmaceutical candidates, enabling faster time-to-market and expanded capabilities in alpha-particle therapies.

Clinical collaboration Target academic institutions and contract research organizations for Phase 1 imaging and Phase 1/2a therapy trials in metastatic melanoma and neuroendocrine tumors, offering theranostic solutions that align with precision oncology initiatives.

Nuanced diagnostics Highlight the complementary diagnostic imaging agents built on the same targeting peptides to position end-to-end theranostic packages that support patient selection, treatment personalization, and improved outcome tracking.

Smaller company agility Capitalize on the company’s lean footprint and recent leadership and merger activity to offer flexible collaboration models, rapid decision cycles, and customized manufacturing or subset biotech partnerships.

Funding and visibility Emphasize revenue potential in the $1–$10 million range with a focused pipeline (VMT01 and VMT-α-NET) to attract niche investors, government grants, and clinical development funding aligned with radiopharmaceuticals and precision medicine.